Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
EVAX
EVAX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
EVAX News
Evaxion Looks for New Partner for Gonorrhea Vaccine Following Merck's Withdrawal
Dec 19 2025
Benzinga
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
Dec 19 2025
Globenewswire
Evaxion Retains Global Rights to EVX-B2 After MSD Declines Option
Dec 19 2025
Newsfilter
Evaxion Unveils EVX-04 Cancer Vaccine, Significantly Inhibiting Tumor Growth
Dec 06 2025
Globenewswire
Evaxion Unveils EVX-04 Cancer Vaccine, Prevents Tumor Growth
Dec 06 2025
Newsfilter
Post-Market Highlights: Jasper, NRx, Unicycive, Spruce, Evaxion, Solana, and Protara See Gains After Trading Hours
Dec 02 2025
NASDAQ.COM
Evaxion unveils new immune findings from phase 2 trial of AI-crafted personalized cancer vaccine EVX-01
Nov 07 2025
Newsfilter
Evaxion to Release Business Update and Q3 2025 Financial Results on November 6, 2025
Oct 31 2025
Newsfilter
Draganfly Analyst Starts Coverage with Optimism; Check Out Thursday's Top 3 Initiations
Oct 30 2025
Benzinga
Evaxion appoints Helen Tayton-Martin as its new CEO
Oct 27 2025
SeekingAlpha
Natural Killer Cell Treatments Drive $254B Shift in Immunotherapy Market
Oct 17 2025
Newsfilter
HC Wainwright & Co. Reaffirms Buy Rating on Evaxion, Increases Price Target to $16
Sep 25 2025
Benzinga
Evaxion Grants Merck & Co. License for Vaccine Candidate EVX-B3
Sep 25 2025
NASDAQ.COM
Merck Secures Evaxion Vaccine Candidate Through Licensing Agreement Valued at Up to $600 Million
Sep 25 2025
SeekingAlpha
Evaxion to Showcase at Multiple Conferences in Late 2025
Aug 27 2025
Newsfilter
Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments
Jul 29 2025
Newsfilter
Show More News
